A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT05085028 · RECRUITING
Trial details
- NCT number
- NCT05085028
- Sponsor
- Imperial College London
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-23
- Primary completion
- 2027-05-31
- Enrollment
- 1750
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.